Table 3.
Absolute and relative values of oral medication, injectable medication and metformin-based combination therapies in the treatment of type 2 diabetes mellitus in the Diabetes Registry Tyrol by age groups
| Class | 18–39 years, n (%) | 40–59 years, n (%) | 60–79 years, n (%) | 80–99 years, n (%) |
| Oral medication | ||||
| Oral antidiabetic drugs | 108 (58.4) | 1672 (75.1) | 4297 (70.6) | 1331 (56.1) |
| Metformin or gliptins | 101 (54.6) | 1541 (69.2) | 3859 (63.4) | 1034 (43.6) |
| Metformin | 100 (54.1) | 1446 (65.0) | 3347 (55.0) | 690 (29.1) |
| Gliptins | 21 (11.4) | 590 (26.5) | 1852 (30.5) | 604 (25.4) |
| SGLT-2i | 22 (11.9) | 437 (19.6) | 753 (12.4) | 58 (2.4) |
| Sulfonylurea analogs | 7 (3.8) | 136 (6.1) | 528 (8.7) | 323 (13.6) |
| Glitazones | 4 (2.2) | 116 (5.2) | 239 (3.9) | 40 (1.7) |
| Glucosidase inhibitors | 0 (0) | 4 (0.2) | 21 (0.4) | 14 (0.6) |
| Injectable medication | ||||
| Insulin or analogs | 56 (30.3) | 754 (33.9) | 2623 (43.1) | 1267 (53.4) |
| Insulin analogs | 42 (22.7) | 578 (26.0) | 2092 (34.4) | 933 (39.3) |
| Insulin | 40 (21.6) | 498 (22.4) | 1822 (30.0) | 818 (34.5) |
| GLP-1a | 8 (4.3) | 109 (4.9) | 174 (2.9) | 10 (0.4) |
| Metformin-based combinations | ||||
| Metformin and gliptins | 20 (10.8) | 490 (22.0) | 1343 (22.1) | 262 (11.0) |
| Metformin and (insulin/analogs) | 27 (14.6) | 426 (19.1) | 1153 (19.0) | 252 (10.6) |
| Metformin and SGLT-2i | 19 (10.3) | 372 (16.7) | 619 (10.2) | 39 (1.6) |
| Metformin and sulfonylurea | 5 (2.7) | 87 (3.9) | 320 (5.3) | 91 (3.8) |
| Metformin and SGLT-2i and gliptin | 4 (2.2) | 154 (6.9) | 283 (4.7) | 18 (0.8) |
| Metformin and glitazone | 3 (1.6) | 89 (4.0) | 168 (2.8) | 21 (0.9) |
| Metformin and GLP-1a | 8 (4.3) | 79 (3.6) | 117 (1.9) | 6 (0.3) |
| Metformin and SGLT-2i and GLP-1a | 5 (2.70) | 27 (1.2) | 41 (0.7) | 2 (0.1) |
| Total | 185 (100) | 2227 (100) | 6083 (100) | 2374 (100) |
GLP-1a, glucagon-like peptide-1 agonist; SGLT-2i, sodium/glucose cotransporter 2 inhibitor.